Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
20 May, 2019 14:16 IST
Lupin gets USFDA approval for Doxercalciferol injection
Source: IRIS | 05 Nov, 2018, 04.30PM
Comments  |  Post Comment

Pharma major Lupin announced that it has received approval for its Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials from the United States Food and Drug Administration (FDA) to market a generic version of Sanofi Genzyme's Hectorol Injection.

Lupin’s Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vial is the generic version of Genzyme's Hectorol Injection. It is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.

Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials had annual sales of approximately USD 133 million in the US (IQVIA MAT September 2018).

Shares of the company gained Rs 4.05, or 0.48%, to settle at Rs 853.45. The total volume of shares traded was 67,037 at the BSE (Monday).



Lupin Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer